|
Match
|
Document |
Document Title |
|
|
US20120245181 |
OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME
This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
|
|
|
US20130090346 |
Use of 1H-quinazoline-2,4-diones
The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy.
|
|
|
US20110294797 |
REVERSE-TURN MIMETICS AND METHOD RELATING THERETO
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures...
|
|
|
US20110257185 |
REVERSE-TURN MIMETICS AND METHOD RELATING THERETO
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures...
|
|
|
US20110263609 |
Methods of Identifying and Treating Individuals Exhibiting NUP214-ABL1 Positive T-Cell Malignancies with Protein Tyrosine Kinase Inhibitors and Combinations Thereof
The invention described herein relates to diagnostic and treatment methods and compositions useful in the management of disorders, for example cancers, involving NUP214-ABL1 positive T-cell...
|
|
|
US20120282387 |
ACIDIC EXTRACTS AND BEVERAGES CONTAINING 2,5-PIPERAZINEDIONE,3,6-BIS(PHENYLMETHYL)-(3S,6S)-
The present invention aims to provide extracts available for use in acidic beverage production and containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-,(3S,6S)-, which is a useful substance with...
|
|
|
US20110251204 |
Modulators of G Protein-Coupled Receptor 88
The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled...
|
|
|
US20110251196 |
Modulators of G Protein-Coupled Receptor 88
The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled...
|
|
|
US20110245264 |
Modulators of G Protein-Coupled Receptor 88
The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled...
|
|
|
US20110281872 |
COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.
|
|
|
US20110112127 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds...
|
|
|
US20100298329 |
TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS
The invention provides compositions and methods for treating cancer. Aspects of the invention relate to therapeutic compositions comprising tolperisone and related compounds. Aspects of the...
|
|
|
US20110263853 |
HPLC METHOD FOR THE ANALYSIS OF BOSETAN AND RELATED SUBSTANCES AND USE OF THESE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS
The present invention relates to a new HPLC method for the analysis of the drug substance bosentan and related substances and to the use of said substances as reference standards and markers.
|
|
|
US20110046144 |
IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS
Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-IR enzyme and are useful for the...
|
|
|
US20130034495 |
ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL
Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods...
|
|
|
US20110251216 |
COMPOSITIONS AND METHODS FOR INHIBITING EZH2
The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in cancer (e.g.,...
|
|
|
US20110263530 |
Aurora Kinase Modulators and Method of Use
The present invention relates to chemical compounds having a general formula I wherein A1, A2, C1, C2, D, L1, L2, Z and R3, R4, R6, R7 and R8 are defined herein, which are capable of modulating...
|
|
|
US20110319418 |
PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN
Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D,...
|
|
|
US20110319400 |
PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN
Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D,...
|
|
|
US20110268699 |
METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES
Methods and pharmaceutical compositions for treating multiple sclerosis are described. The methods and pharmaceutical compositions include a therapeutically effective amount of one or more...
|
|
|
US20110280815 |
COMPOSITION FOR INHIBITING MELANIN PRODUCTION AND APPLICATION THEREOF
The present invention provides a composition for inhibiting melanin production to promote skin whitening, which is characterized by containing compounds represented by formula (I): wherein R1, R2...
|
|
|
US20120220610 |
INHIBITIONS OF GLUTAMINASE C
The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the...
|
|
|
US20050049240 |
Tetrahydroisochinolines, their production and the use thereof as analgesics
The invention relates to novel tetrahydroisoquinolines, to processes for their preparation and to their use for producing pharmaceuticals for the treatment and/or prophylaxis of diseases, in...
|
|
|
US20120270237 |
METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS
The present invention relates to immobilization compounds (I), immobilization products and preparations thereof as well as methods and uses for the identification of kinase interacting compounds or...
|
|
|
US20120083006 |
METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS
The present invention relates to immobilization compounds (I), immobilization products and preparations thereof as well as methods and uses for the identification of kinase interacting compounds or...
|
|
|
US20120309742 |
USE OF METABOTROPIC GLUTAMATE RECEPTORS
The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.
|
|
|
US20120277191 |
FORMS OF CIDOFOVIR
Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various...
|
|
|
US20120157415 |
New Crystalline Form of Pemirolast
There is provided a hemihydrate form of the sodium salt of pemirolast.
|
|
|
US20120095077 |
METHODS AND COMPOSITIONS RELATED TO MODIFIED GUANINE BASES FOR CONTROLLING OFF-TARGET EFFECTS IN RNA INTERFERENCE
Disclosed are compositions and methods related to modified nucleobases. Also disclosed are compositions and methods related to modified interfering RNAs. Also disclosed are compositions and methods...
|
|
|
US20120264765 |
Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis
The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral...
|
|
|
US20120015951 |
Polymorphs of Brimonidine Pamoate
A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular...
|
|
|
US20120220613 |
METHOD FOR DETERMINING SENSITIVITY TO AN ANTICANCER AGENT
To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an...
|
|
|
US20110003395 |
SPECIFIC ANALYSIS OF ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW
Labeling reagents, sets of labeling reagents, and labeling techniques are provided for the relative quantitation, absolute quantitation, or both, of ketone or aldehyde compounds including, but not...
|
|
|
US20110098280 |
2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS
Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
|
|
|
US20110152258 |
Compounds and Methods for Kinase Modulation, and Indications Therefor
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds...
|
|
|
US20110295001 |
Method for Producing Triazine Carbamates Using Chloroformates
The present invention relates to a method for producing triazine carbamates by conversion of at least one triazine with at least one chloroformate in the presence of at least one alkaline or...
|
|
|
US20120202287 |
Stem Cell Culture Methods
The invention provides methods for reversibly inhibiting stem cell differentiation wherein a compound of formula (I) is contacted with a stem cell. The invention further provides a method for...
|
|
|
US20120264218 |
INDUCTION OF PLURIPOTENT CELLS
The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we...
|
|
|
US20120122847 |
AURORA KINASE MODULATORS AND METHOD OF USE
The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of m...
|
|
|
US20110294837 |
Aurora Kinase Modulators and Methods of Use
The present invention relates to chemical compounds having a general formula I wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating...
|
|
|
US20120022087 |
AMORPHOUS AMBRISENTAN
The invention relates to amorphous ambrisentan, preferably together with a surface stabiliser in the form of a stable intermediate. The invention further relates to methods of producing stable...
|
|
|
US20130085150 |
ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B′, X, Y, R1, R2, R2′, R3, R3′, R4, R4′, R5, R5′m, n, or p are as defined herein, are useful for treat...
|
|
|
US20130053348 |
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin...
|
|
|
US20110172238 |
BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B′, X, Y, R1, R1′, R2, R2′, R3, R3′, R5, R5′, R6, m, n, or p are as defined herein, a...
|
|
|
US20120058939 |
AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and...
|
|
|
US20110003737 |
AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and...
|
|
|
US20110195932 |
Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various...
|
|
|
US20120282629 |
Enhancers of Protein Degradation
The present invention relates to compounds suitable for modulating huntingtin protein processing and useful for treating or preventing huntingtin-related disorders. The invention provides...
|
|
|
US20120269724 |
COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS
The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another...
|
|
|
US20130126350 |
Mediator For Test Sensor
A method of forming a 3-phenylimino-3H-phenothiazine or a 3-phenylimino-3H-phenoxazine mediator includes providing a first reactant including phenothiazine or phenoxazine, providing a first...
|